Prof. David Devos

Prof. David Devos is a neuropharmacologist, specialist in Parkinson's diseas, movement disorders, development of new therapies and biomarkers at the University Hospital of Lille.

Functions Neurologist specialized in movement disorders, Professor of clinical and fundamental pharmacology
Expertises and fields of research Development of new therapeutic strategies (symptomatic and disease-modifying) and of biomarkers in Parkinson's disease and amyotrophic lateral sclerosis using translational studies, clinical studies and phase I and II therapeutic trials
Number of publications  > 200
Number of national and international projects    
  • 30 studies including 14 multicenter trials and 14 as coordinator (10 ongoing projects), 4 project funded by the European commission (H2020) including 2 in neurosciences (iron, ferroptotic cell death), 1 large European clinical trial FAIRPARK-2 and 1 on Covid-19 diagnostic.
  • 6 patents leading to 3 industrial transfers with co-foundation of 3 start-ups (InBrain Pharma for brain perfusion, InVenis Biotherapies for platelet-based biotherapies and Cordial-IT for diagnostic tools).
Some key projects
  • PREDISTIM: Multicentric study of the predictive factors of the therapeutic response to subthalamic stimulation on the long-term quality of life and study of the pharmacogenetic factors of the L-dopa treatment response in Parkinson’s disease Protocol ID: 2013-A00193-42; NCT02360683
  • PULSE: Multicentric study of the Pronostic valUe of biomarkers in amyotrophic Lateral Sclerosis & Endophenotypic study Protocol ID: 2013-A00969-36; NCT02360891
  • FAIR-PARK-II: European multicentric study of Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone; Identifier: NCT02655315
  • FAIR-ALS-II: Conservative Iron Chelation by Deferiprone as a Disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial on 240 patients. Protocol ID: 2017-003763-35; NCT03293069
  • PACTE-I: Potentiation of cognitive functions in healthy elderly by association of methylphenidate and cognitive training: Proof of concept study in order to develop a synergic symptomatic treatment of cognitive disorders before dementia. Protocol ID: 2015_81; NCT03280251
  • PRION-IRON: European funds from (Network of Centres of Excellence in Neurodegeneration (CoEN) (PRION like propagation of synucleinopathy associated with ferroptosis, the IRON dependent cell death): to develop new therapeutic strategies against ferroptosis
  • PARKINSUN: Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care. Protocol ID: 2018_74 ; NCT04179695
  • DIVE: Evaluation of the safety and efficacy of continuous dopaminergic stimulation by intracerebroventricular administration of anaerobic dopamine conserved in Parkinson's disease at the motor fluctuation stage. Trial Registration: Protocol ID: 2018_49; French Ethical Committee; 2020-000155-12; ID: NCT04332276, academic patents with industrial transfer with a start-up creation: InBrain Pharma 
  • GIFT project (biothérapie: Growth factor preparations from platelets & neuroprotective strategies) 3 patents and one industrial transfer in progress with start-up creation InVenis biotherapies.
  • CorDial-1 patent (methods for detecting a target in a sample using mutated nanobodies) with one industrial transfer in progress with start-up creation CorDial-IT


Updated on 10 February 2023